Back to Search Start Over

Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using 18F-FDG-PET-CT and/or diffusion-weighted MRI

Authors :
Jonas A. Castelijns
Marjolein J.E. Greuter
Otto S. Hoekstra
Veerle M.H. Coupé
Emile F.I. Comans
Remco de Bree
Pim de Graaf
Charlotte S. Schouten
CCA - Cancer Treatment and quality of life
APH - Quality of Care
Epidemiology and Data Science
Otolaryngology / Head & Neck Surgery
Radiology and nuclear medicine
Amsterdam Neuroscience - Neuroinfection & -inflammation
AGEM - Re-generation and cancer of the digestive system
APH - Methodology
ACS - Heart failure & arrhythmias
Source :
BMC Cancer, 17(1):256. BioMed Central, BMC Cancer, 17. BioMed Central, BMC Cancer, BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017), BMC Cancer, 17, Greuter, M J E, Schouten, C S, Castelijns, J A, de Graaf, P, Comans, E F I, Hoekstra, O S, de Bree, R & Coupé, V M H 2017, ' Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using 18 F-FDG-PET-CT and/or diffusion-weighted MRI ', BMC Cancer, vol. 17, no. 1, 256 . https://doi.org/10.1186/s12885-017-3254-0
Publication Year :
2017

Abstract

Contains fulltext : 174260.pdf (Publisher’s version ) (Open Access) BACKGROUND: Considerable variation exists in diagnostic tests used for local response evaluation after chemoradiation in patients with advanced oropharyngeal cancer. The yield of invasive examination under general anesthesia (EUA) with biopsies in all patients is low and it may induce substantial morbidity. We explored four response evaluation strategies to detect local residual disease in terms of diagnostic accuracy and cost-effectiveness. METHODS: We built a decision-analytic model using trial data of forty-six patients and scientific literature. We estimated for four strategies the proportion of correct diagnoses, costs concerning diagnostic instruments and the proportion of unnecessary EUA indications. Besides a reference strategy, i.e. EUA for all patients, we considered three imaging strategies consisting of 18FDG-PET-CT, diffusion-weighted MRI (DW-MRI), or both 18FDG-PET-CT and DW-MRI followed by EUA after a positive test. The impact of uncertainty was assessed in sensitivity analyses. RESULTS: The EUA strategy led to 96% correct diagnoses. Expected costs were euro468 per patient whereas 89% of EUA indications were unnecessary. The DW-MRI strategy was the least costly strategy, but also led to the lowest proportion of correct diagnoses, i.e. 93%. The PET-CT strategy and combined imaging strategy were dominated by the EUA strategy due to respectively a smaller or equal proportion of correct diagnoses, at higher costs. However, the combination of PET-CT and DW-MRI had the highest sensitivity. All imaging strategies considerably reduced (unnecessary) EUA indications and its associated burden compared to the EUA strategy. CONCLUSIONS: Because the combined PET-CT and DW-MRI strategy costs only an additional euro927 per patient, it is preferred over immediate EUA since it reaches the same diagnostic accuracy in detecting local residual disease while leading to substantially less unnecessary EUA indications. However, if healthcare resources are limited, DW-MRI is the strategy of choice because of lower costs while still providing a large reduction in unnecessary EUA indications.

Details

Language :
English
ISSN :
14712407
Database :
OpenAIRE
Journal :
BMC Cancer, 17(1):256. BioMed Central, BMC Cancer, 17. BioMed Central, BMC Cancer, BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017), BMC Cancer, 17, Greuter, M J E, Schouten, C S, Castelijns, J A, de Graaf, P, Comans, E F I, Hoekstra, O S, de Bree, R & Coupé, V M H 2017, ' Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using 18 F-FDG-PET-CT and/or diffusion-weighted MRI ', BMC Cancer, vol. 17, no. 1, 256 . https://doi.org/10.1186/s12885-017-3254-0
Accession number :
edsair.doi.dedup.....141944df08c456aad4ce4e62f8636474